Heartland Bank & Trust Co Makes New Investment in DaVita Inc. $DVA

Heartland Bank & Trust Co acquired a new stake in DaVita Inc. (NYSE:DVA) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 2,284 shares of the company’s stock, valued at approximately $351,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Gen Wealth Partners Inc boosted its stake in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock worth $100,000 after buying an additional 80 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares during the period. Orion Porfolio Solutions LLC boosted its position in DaVita by 4.4% in the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock worth $268,000 after purchasing an additional 99 shares during the last quarter. Root Financial Partners LLC boosted its position in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in DaVita by 3.9% in the 1st quarter. Bessemer Group Inc. now owns 2,962 shares of the company’s stock valued at $456,000 after purchasing an additional 110 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DaVita stock opened at $236.93 on Friday. The stock has a market capitalization of $15.21 billion, a P/E ratio of 21.98, a P/E/G ratio of 0.78 and a beta of 0.88. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $239.64. The stock’s 50-day simple moving average is $209.94 and its 200 day simple moving average is $164.49.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent analyst reports. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. UBS Group raised their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Truist Financial boosted their target price on shares of DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Finally, Barclays increased their target price on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $216.50.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.